Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

stage I non-small cell lung cancerstage II non-small cell lung cancerlimited stage small cell lung cancerstage IIIA non-small cell lung cancerstage IIIB non-small cell lung canceranorexiacachexia

Interventions

megestrol acetateDrug

radiation therapyRadiation

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 120 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed lung cancer * Unresectable stage I-IIIB non-small cell lung cancer (NSCLC) * Resected stage I-IIIB NSCLC * Limited stage small cell lung cancer * Planned radiotherapy with a total dose of at least 5,000 cGy in fraction sizes of no greater than 200 cGy each * No distant metastases * No significant ascites, pleural effusions, or edema that would inhibit oral food intake or invalidate weight determinations PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * ECOG 0-2 Life expectancy: * More than 3 months Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Cardiovascular: * No uncontrolled hypertension * No active thromboembolic disease * No myocardial infarction within the past 3 months * No prior congestive heart failure or thromboembolic events Pulmonary: * No prior pulmonary edema Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other malignancy within the past 3 years except curatively treated carcinoma in situ of the cervix or non-melanoma skin cancer * No uncontrolled diabetes with glycosylated hemoglobin greater than 10% * No Cushing's syndrome * No dietary restrictions (e.g., salt, sugar, or lipid) * No other serious medical or psychiatric illness that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Endocrine therapy Endocrine therapy: * At least 12 months since prior corticosteroids, estrogens, progestins, or other steroid hormone except as antiemetic prior to chemotherapy * No concurrent corticosteroids, estrogens, progestins, or other steroid hormone except as antiemetic prior to chemotherapy Radiotherapy: * See Disease Characteristics * No prior radiotherapy to lung Surgery: * See Disease Characteristics * More than 14 days since prior surgery

Sponsors & Collaborators

National Cancer Institute (NCI)
NIHcollaborator
Wake Forest University Health Sciences
Otherlead

Study Sites (1)

Comprehensive Cancer Center at Wake Forest University

Winston-Salem, North Carolina, 27157-1082, United States

MeSH Terms

Conditions

AnorexiaCachexiaLung NeoplasmsCarcinoma, Non-Small-Cell Lung

Interventions

Megestrol AcetateRadiotherapy

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and SymptomsWeight LossBody Weight ChangesBody WeightThinnessRespiratory Tract Neoplasms

Study Officials

Edward G. Shaw, MD
Wake Forest University Health Sciences
STUDY CHAIR

Enrollment

25 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Purpose: SUPPORTIVE CARE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 8, 2002

First Posted

August 6, 2003

Study Start

September 1, 2000

Actual (reported)

Primary Completion

Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

Primary Completion

Study Completion

First Posted

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

Primary Completion

Study Completion

First Posted

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations